Background\ud Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal\ud elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and\ud cardiovascular disease. Recent genome-wide association scans have found common genetic\ud variants of SLC2A9 to be associated with increased serum urate level and gout. The SLC2A9 gene\ud encodes a facilitative glucose transporter, and it has two splice variants that are highly expressed\ud in the proximal nephron, a key site for urate handling in the kidney. We investigated whether\ud SLC2A9 is a functional urate transporter that contributes to the longstanding association\ud between urate and blood pressure in man.\ud Methods and Findings\ud We expressed both SLC2A9 splice variants in Xenopus laevis oocytes and found both isoforms\ud mediate rapid urate fluxes at concentration ranges similar to physiological serum levels (200–500\ud lM). Because SLC2A9 is a known facilitative glucose transporter, we also tested whether glucose\ud or fructose influenced urate transport. We found that urate is transported by SLC2A9 at rates 45-\ud to 60-fold faster than glucose, and demonstrated that SLC2A9-mediated urate transport is\ud facilitated by glucose and, to a lesser extent, fructose. In addition, transport is inhibited by the\ud uricosuric benzbromarone in a dose-dependent manner (Ki=27μM). Furthermore, we found\ud urate uptake was at least 2-fold greater in human embryonic kidney (HEK) cells overexpressing\ud SLC2A9 splice variants than nontransfected kidney cells. To confirm that our findings were due\ud to SLC2A9, and not another urate transporter, we showed that urate transport was diminished\ud by SLC2A9-targeted siRNA in a second mammalian cell line. In a cohort of men we showed that\ud genetic variants of SLC2A9 are associated with reduced urinary urate clearance, which fits with\ud common variation at SLC2A9 leading to increased serum urate. We found no evidence of\ud association with hypertension (odds ratio 0.98, 95% confidence interval [CI] 0.9 to 1.05, p > 0.33)\ud by meta-analysis of an SLC2A9 variant in six case–control studies including 11,897 participants. In\ud a separate meta-analysis of four population studies including 11,629 participants we found no\ud association of SLC2A9 with systolic (effect size -0.12 mm Hg, 95% CI -0.68 to 0.43, p=0.664) or\ud diastolic blood pressure (effect size -0.03 mm Hg, 95% CI -0.39 to 0.31, p = 0.82).\ud Conclusions\ud This study provides evidence that SLC2A9 splice variants act as high-capacity urate\ud transporters and is one of the first functional characterisations of findings from genome-wide\ud association scans. We did not find an association of the SLC2A9 gene with blood pressure in this\ud study. Our findings suggest potential pathogenic mechanisms that could offer a new drug\ud target for gout
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.